Role of Simvastatin as an Immunomodulator in Type 2 Diabetes

Diabetes Care

Volumn 27, Issue 4, 2004, Pages 908-913

  Lopes Virella, Maria F ^a,b,c   Mironova, Marina ^a   Stephan, Elias ^a   Durazo Arvizu, Ramon ^c   Virella, Gabriel ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBODY; ATENOLOL; CLARITHROMYCIN; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROMYCIN; FUROSEMIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; ITRACONAZOLE; KETOCONAZOLE; LEVOTHYROXINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEFAZODONE; SIMVASTATIN; TRIAMTERENE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DIET THERAPY; DRUG ACTIVITY; EXERCISE; FEMALE; HUMAN; LIVER FUNCTION TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIGEN-ANTIBODY COMPLEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; SIMVASTATIN; TIME FACTORS;

EID: 1842433723     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.4.908     Document Type: Article

References (25)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
2. Vinik A, Flemmer M: Diabetes and macrovascular disease. J Diabetes Complications 16:235-245, 2002
3. Lopes-Virella MF, Klein RL, Virella G: Modification of lipoproteins in diabetes. Diabetes Metab Rev 12:69-90, 1996
4. Mullarkey CJ, Edelstein D, Brownlee M: Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932-939, 1990
5. Baynes JW, Thorpe SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708-1716, 2000
6. Lopes-Virella MF, Virella G: The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci 8:S750-S768, 2003
7. Yla-Herttuala S, Palinski W, Rosenfeld ME, ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095, 1989
8. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14:32-40, 1994
9. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF, DCCT/EDIC Research Group: Autoimmune response to advanced glycosylation end-products of human low density lipoprotein. J Lipid Res 443:487-493, 2003
10. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF: Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49:1033-1041, 2000
11. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M: Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 95:135-144, 2000
12. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 90:165-172, 1999
13. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF: Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48:1454-1458, 1999
14. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620, 1997
15. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial: the Care Investigators. Circulation 98:2513-2519, 1998
16. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402, 2000
17. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M: In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21:1327-1332, 2001
18. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF: Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 23: 95-101, 1993
19. Koskinen S, Enockson C, Lopes-Virella MF, Virella G: Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diagn Lab Immunol 5:817-822, 1998
20. Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF: Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol 85: 73-82, 1997
21. Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF: Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 19:1600-1607, 1999
22. Virella G, Bierer B: The induction of an immune response: antigens, lymphocytes, and accessory cells. In Introduction to Medical Immunology. Virella G, Ed. New York, Marcel Dekker, 2001, p. 51-76
23. Virella G, Tsokos G: Immune complex diseases. In Medical Immunology. Virella G, Ed. New York, Marcel Dekker, 2001, p. 453-471
24. Virella G, Atchley DH, Koskinen S, Zheng D, Lopes-Virella M: Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 105:81-92, 2002
25. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999